SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, ...

Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), ...

Company Overview - Bionano Genomics, Inc. is a provider of genome analysis solutions aimed at addressing complex questions in biology and medicine [3] - The company's mission is to transform genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] Upcoming Conference - Erik Holmlin, PhD, the CEO of Bionano, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - The presentation is scheduled from 3:00 p.m. to 3:30 p.m. ET [2] - A recording of the session will be available on the Bionano website for at least 30 days following the conference [2]

Core Viewpoint - Bionano Genomics, Inc. has announced the release of upgraded software versions VIA 7.2 and Solve 3.8.3, along with enhancements to its Stratys Compute server, aimed at improving genomic data analysis and interpretation speed, particularly for hematological malignancies and constitutional genetic disorders [1][2]. Group 1: Software Upgrades - VIA 7.2 automates variant calling, annotation, and interpretation using AI, enhancing the contextualization of variant calls across various data types [1][4]. - Solve 3.8.3 expands its control database of background structural variants (SVs) by 18%, improving sensitivity, specificity, and resolution for SV detection [4][5]. - The upgrades to the Stratys Compute server double the number of cancer samples that can be analyzed per week and expand functionality to include analysis pipelines previously available only on CPU versions [4][5]. Group 2: Company Mission and Offerings - Bionano aims to transform genome analysis through optical genome mapping (OGM) solutions, diagnostic services, and software, catering to basic, translational, and clinical research [3]. - The company provides an industry-leading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology [3].

Core Insights - Bionano Genomics participated in the European Cytogenomics Conference (ECA) 2025, highlighting the growing interest and advancements in Optical Genome Mapping (OGM) technology within the clinical cytogenomics community [1][2][5] Group 1: Conference Highlights - The ECA 2025 featured two hands-on workshops focused on Bionano's VIA™ analytical suite for structural variation analysis, co-led by Bionano representatives and key opinion leaders [2] - A total of 16 studies were presented at the conference, an increase from 14 studies in 2023 and 9 studies in 2021, indicating a rising trend in OGM research contributions [2][5] - The scientific program included various presentations on the applications of OGM in diagnosing and treating conditions like Multiple Myeloma and Non-Hodgkin Lymphoma [3][5] Group 2: Industry Implications - The increasing number of contributions at the ECA conference suggests a broader shift towards comprehensive genome-wide structural variant analysis using OGM, which can uncover structural variants often missed by traditional methods [5][10] - Bionano's president emphasized the validation and inspiration derived from more institutions adopting OGM to address complex genetic cases, indicating a positive trajectory for the technology's acceptance in clinical settings [5][10] - Bionano's mission is to transform genome analysis through OGM solutions, diagnostic services, and software, positioning the company as a leader in the field [7]

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most c ...